The partnership will improve care for patients with pancreatic cancer myTomorrows, a global health technology company connecting patients with all possible treatment options, has announced a new partnership with Pancreatic Cancer Europe, a multi-stakeholder platform that brings together experts from all over Europe to improve care for patients with pancreatic cancer. Through the new partnership, Pancreatic Cancer Europe (PCE) will utilise myTomorrows’ database of ongoing clinical trials to equip patients, caregivers and healthcare professionals (HCPs) with up-to-date, accessible information about pre-approval treatments that may be relevant to them. The partnership with the European patient advocacy group and myTomorrows will help to expand access to all possible treatment options for patients suffering from a variety of life-threatening illnesses. For pancreatic cancer patients and HCPs, the partnership will help make the process of identifying and understanding the existing clinical trial options easier. Pancreatic cancer is the fourth leading cause of cancer deaths, ...
Acelyrin has shared positive results from a late-stage study of its IL-17A inhibitor izokibep in hidradenitis suppurativa (HS), but has said it will not be moving forward with the asset in this indication. Estimated to affect about 1% of the population in most studied countries, HS is a chronic inflammatory skin condition that causes painful nodules and abscesses. In the phase 3 trial, izokibep demonstrated statistically significant responses across multiple efficacy endpoints at week 12, with 33% of patients being treated with izokibep 160mg weekly achieving at least a 75% reduction in total abscess and inflammatory nodule count (HiSCR75) compared to 21% of those receiving placebo. Results also showed that 25% and 22% of izokibep-treated patients achieved HiSCR90 and HiSCR100, respectively, compared to 9% and 8% in the placebo cohort. The announcement comes shortly after the drug demonstrated promising results in a phase 2b/3 study for psoriatic arthritis (PsA), a ...
Today (August 26th), Ansukang Medical (Suzhou) Co., Ltd. (hereinafter referred to as “Ansukang Medical”) announced the completion of a new round of 100 million yuan financing. The round of financing is jointly invested by Taiping Innovation, Junlian Capital, and Shengjing Jiacheng. The funds raised from the financing will mainly be used for promoting the market of unmanned ultrasonic knives, building a new generation of energy platforms, and preparing production capacity. Founded in 2020, Ansukang Medical has been focusing on the research and development of innovative medical devices since its establishment. It is an innovative medical device company based on its own core technology system, committed to providing Chinese medical workers with better and more convenient medical devices. At present, the main product launched by Ansukang Medical is the new generation of non host ultrasonic knife, which is also the world’s first split type non host ultrasonic knife. Compared with similar ...
Eli Lilly and Company has announced the availability of Zepbound (tirzepatide) in 2.5mg and 5mg single-dose vials for self-pay for adults with obesity. The move significantly expands the supply of Zepbound in response to high demand and offers a more affordable option for those who self-pay. The vials are priced a minimum of 50% lower than the list price of other incretin medicines for obesity. Lilly has introduced a new self-pay pharmacy component within LillyDirect, enabling patients with a valid prescription to purchase Zepbound directly. The initiative ensures the authenticity of the medicine and safeguards patients from counterfeit products. Lilly also announced its commitment to ensuring that Zepbound is used appropriately and not for cosmetic weight loss, implementing a multi-step verification process for dispensing. The 2.5mg Zepbound vial costs $399 for a four-week supply while the 5mg dose costs $549 – both representing significant savings compared to other treatments. The ...
Pfizer has launched a new digital platform, PfizerForAll, aimed at simplifying the process of accessing healthcare for millions of Americans. The platform provides an integrated experience for managing health and wellness, particularly for those affected by common illnesses and seeking adult vaccinations. PfizerForAll consolidates critical resources and services, enabling individuals and families to take health actions such as obtaining care, filling prescriptions and finding potential savings on Pfizer medicines. The platform operates within the US healthcare system and is developed in partnership with healthcare organisations. Patients using PfizerForAll can leverage their existing insurance and pharmacy programmes while benefiting from new direct services from partners such as UpScriptHealth, Alto Pharmacy and Instacart. At its inception, PfizerForAll offers same-day appointments with healthcare professionals for in-person or telehealth consultations, home delivery of prescription medicines, and scheduling for adult vaccinations against Covid-19, flu, RSV [respiratory syncytial virus] and pneumococcal pneumonia. The platform will also ...
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Astellas Pharma’s Vyloy (zolbetuximab) as part of a first-line combination treatment for a subset of gastric cancer patients. The monoclonal antibody has been authorised for use alongside chemotherapy to treat adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma whose tumours are claudin 18.2 positive. In the UK, adenocarcinomas, which develop from cells in the innermost lining of the stomach, account for most cases of gastric cancer, with around 6,600 people diagnosed every year. Most cases go undetected until an advanced stage, as the disease rarely causes early symptoms and tends to develop slowly over a number of years. Vyloy is now the only licensed treatment to target the claudin 18.2 protein, which is expressed in gastric, oesophageal, lung and ovarian tissues, and is administered intravenously every two to three ...
Using a genomic approach, researchers have developed a way to simultaneously track the spread of multiple common antibiotic-resistant bacteria in hospitals. Current methods culture and sequence all pathogens separately so the new sequencing technique could help to prevent and manage hospital infections more quickly and effectively. Published in the Lancet Microbe, the proof-of-concept study from the Wellcome Sanger Institute, the University of Oslo, Fondazione IRCCS Policlinico San Matteo in Italy and collaborators captured the whole population of pathogenic bacteria found in the gut, upper airways and lungs of patients in multiple hospital intensive care units (ICUs) and ordinary wards during the first wave of the COVID-19 pandemic in 2020. The team found that, with most ICU patients colonised by several treatment-resistant bacteria and all patients colonised by at least one, they were able to determine which type of bacteria each patient had. Antimicrobial resistance (AMR) occurs when bacteria, viruses, fungi ...
Lung cancer ranks among the most prevalent and fatal cancers worldwide. Current treatment strategies for lung cancer patients rely on pathological examinations, which can reveal genetic mutations specific to the patient’s cancer, facilitating personalized treatment approaches. Over the last few years, pathology has evolved dramatically due to digital advancements, making traditional microscopes obsolete. Tissue samples are now digitized and analyzed via computer screens, which is essential for employing sophisticated artificial intelligence (AI)-based analytical methods. These AI technologies can extract additional insights from pathological tissue sections that were previously unattainable. A team of researchers at the University of Cologne (Cologne, Germany) has developed an AI-driven digital pathology platform that can revolutionize the analysis of lung cancer tissues. This platform utilizes newly developed algorithms to perform fully automated examination of digitized lung cancer tissue sections, offering faster and more precise analyses than traditional methods. Detailed in their publication in the journal Cell ...
In the field of cardiovascular health, some individuals fall into an ambiguous “intermediate zone” of risk for heart attacks or strokes—neither distinctly low nor high-risk, yet potentially on the cusp of heart disease. This grey area calls for improved methodologies for accurate risk prediction. Traditionally, risk assessments like the widely recognized Framingham Risk Score have utilized factors such as levels of ‘good’ and ‘bad’ cholesterol to categorize individuals into risk groups. However, these conventional tools have several limitations, especially in identifying the risks for those in this intermediate category. This oversight is particularly critical as heart disease can progress silently, making early detection crucial to avoid late-stage interventions that are less effective. Now, scientists have developed and validated a novel, blood-based risk score based on lipids (fats in the blood). The tool, outlined in a paper published in the Journal of the American College of Cardiology, was developed by scientists ...
Bronchiectasis is the third most common lung condition in the UK but despite this, it is sometimes seen as a ‘hidden’ disease due to a lack of public awareness, investment and research. Now a multi-million-pound clinical trial is set to start in September to investigate whether existing drugs could be used to treat the debilitating lung disease. The disease results in persistent breathing difficulties and repeated lung infections when bronchi – tubes in the lungs – become permanently damaged and widened. There is currently no treatment or cure and, with an ageing population, numbers are increasing. Currently the disease affects one in 200 people in the UK (approximately 200,000), with an increase of 40% over the last ten years and an expected increase of a further 20% over the next decade. Researchers from EMBARC, the European Research Network for bronchiectasis, are working on the AIRNET (Anti-Inflammatory Repurposing Network) project to ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.